GeNeuro SA appointed Gordon S. Francis and Giacomo Di Nepi have agreed to join its Board of Directors. Dr. Gordon Francis has played a key role in the approval of several leading MS treatments, including Gilenya at Novartis, Tysabri at Elan and Rebif for Serono. Dr. Francis started his career in MS at McGill University in Montreal where he headed the MS Clinical Research Center at the Montreal Neurological Institute and followed a neuro-immunology fellowship at UCSF.

Giacomo Di Nepi was most recently Executive Vice President and Managing Director for InterMune in Europe, where he was responsible for building the European organization and leading the launch of Esbriet. Before InterMune, Mr. Di Nepi was CEO of Takeda Pharmaceuticals and before held various roles with Novartis in Europe and the United States. Mr. Di Nepi's early career included 16 years as a Partner with McKinsey & Co.